We Are Going to Be Like the Jetsons!

Sena has been telling me for years that someday soon we’re all going to be like the Jetsons, flying around in bubble-top saucers.

It turns out she may be right.

There’s a news story out about the Jetson Flying Car, which I saw on the Good News Network.  It’s a compact flying car that runs on batteries that are good for about a 20-minute commute. Reports about the altitude the Jetson car can achieve vary, but some say you can get up to about 1500 feet and tour along at a little over 60 miles per hour.

And the Federal Aviation Administration (FAA) says you don’t need a pilot’s license.

Can you say “mass mid-air collisions?”

I doubt there’ll be a lot of buyers because the sticker price is close to $100,000, not counting insurance, extra batteries (you’ll need 8 if you want to swap out to recharge), and attorney fees.

The CEO of the company that makes the Jetson car says you can be a pilot in about 5 minutes.

Funny, that’s about the same time it seems to take the typical semi-truck driver in Canada to get a commercial driver’s license, judging from how busy the tow truck operators are up there.

What if the heavy rescue operators in British Columbia and Toronto had to do recovery work on the Jetson cars? True, the cars aren’t that heavy (about 250 pounds), but what if the number of crashes overwhelms Jamie Davis (think Highway Thru Hell on the Weather Channel)? There wouldn’t be enough tow truck guys to drag all the cars out of the ditches.

Did you know the Jetson Cars come as a DIY kit? That’s right, you have to finish assembly of that expensive toy yourself. You better make sure the batteries are hooked up right since you get just 20 minutes of running time before you need to recharge. Average commutes are longer than 20 minutes.

The Jetson car comes equipped with something called a ballistic parachute, which should be enough to send most potential buyers running out of the showroom. Hey, why would I need a parachute?

No worries, you’re unlikely to be flying much higher than 16 feet anyway, according to the co-founder of the company, eVTOL (electrical vertical take-off and landing).

Let’s see how many traffic signs and trees we can take out on the way to the drug store to pick up some Dramamine.

Only one person (the pilot) can fit in the Jetson Flying Car. And of course, there’s a weight limit; it’s 210 pounds, which is going to raise a hue and cry from the equity, diversity, and inclusion police. There’s no flying family eVTOL—yet. That’s a good thing because there will have be some survivors left to collect on the insurance.

On the bright side, there are no ashtrays to empty, no flat tires to change (nobody remembers how to do that anyway these days), and no radio stations to cycle through. You’re going to be paying too much attention to the birds getting caught in the rotor blades and the bugs splatting on your visor.

That’s assuming you’re a multimillionaire and can afford to fly like the Jetsons. Don’t buzz the pedestrians.

The Path to Asapiprant: Perspiration or Inspiration?

I just found a University of Iowa Health Care announcement about a potential novel treatment to protect older patients from the ravages of Covid-19 infection. According to the announcement:

“An experimental drug that counters immune aging, effectively prevents death in older mice with severe COVID-19, suggesting it may have potential as a therapy to protect older people who are most at risk from the disease. The new findings by researchers with University of Iowa Health Care were published recently in the journal Nature.”

The experimental drug is called Asapiprant. I’m far from knowing anything much about immunology but the path to this discovery reminds me of the work of Ed Wasserman who wrote a book I’ve not yet read but probably should, As If By Design: How Creative Behaviors Really Evolve (2021, Cambridge University Press).

I first found out about Dr. Wasserman from an episode of The University of Iowa’s virtual events of Uncovering Hawkeye History. The title for this one was “Endless Innovation: An R1 Research Institution (1948–1997).” This event series was designed to highlight notable elements of UI’s 175-year history.  

Anyway, in a nutshell, Wasserman’s theory is that innovation is often more about perspiration rather than inspiration. He says it’s often a combination of the 3 C’s: Context, Consequence, and Coincidence. And while I was noodling around on the web, it struck me that this might fit how the Asapiprant innovation developed.

To be sure, the University of Iowa was a critical part of the story of how Asapiprant eventually became an important agent to protect the elderly from immune system aging and thereby decrease the mortality from Covid-19 disease.

I found out the agent was originally called S-555379. It was developed by Shionogi & Co., Ltd as a possible treatment for hay fever several years ago. I think that would be the Coincidence.

But in 2011, Stanley Perlman MD, PhD, professor of microbiology and immunology in the UI Carver College of Medicine, published a paper, which I think is part of the Context:

Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011 Dec;121(12):4921-30. doi: 10.1172/JCI59777. Epub 2011 Nov 21. PMID: 22105170; PMCID: PMC3226008.

This paper was cited by Shionogi in the company’s announcement of their license agreement with BioAge Labs, Inc., posted on January 26, 2021:

“It is known that age-related declines in immune function are significant risk factors that increase morbidity and mortality from infectious diseases2. Therefore, it has been suggested that restoring immune function may reduce the severity of various infectious diseases, including COVID-19. The DP1 receptor has been identified as a drug discovery target that improves age-related declines in immune function in an original AI-driven analysis of longitudinal omics data in humans conducted by BioAge. In addition, in a study conducted at the University of Iowa by Dr. Stanley Perlman in which an existing DP1 receptor antagonist was administered in an aged mouse model of SARS coronavirus (SARS-CoV) infection, the mortality rate of mice was improved and a significant decrease in viral load in the lungs was observed3. Based on these exciting study results, we have concluded a license agreement in expectation of development of this compound as an immunopotentiator for the elderly by drug repositioning.”

And I think part of the Consequence is that BioAge, Inc. has announced that the drug, the name of which was changed to BGE-175 and now called Asapiprant is about to undergo Phase 2 clinical trials for treating older patients hospitalized with COVID-19.

Whether you call it perspiration or inspiration, I think it deserves our admiration.

Featured image picture credit: Pixydotorg.